Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.

Regular administration of cyclophosphamide to NZB/NZW female mice effectively protects against the nephritis that is thought to be a model for human SLE nephritis. Reductions in serologic, histologic, and immunogluorescent parameters of the disease are correlated. Intermittent as well as continuous administration of the drug is effective without the development of leukopenia. Possible mechanisms of drug action and a modified approach to therapy of immune complex disease are discussed.

[1]  D. Katz,et al.  Induction of tolerance to nucleic acid determinants by administration of a complex of nucleoside D-glutamic acid and D-lysine (D-GL). , 1975, Journal of immunology.

[2]  C. K. Osterland,et al.  Modification of NZB-NZW F1 autoimmune disease by development of tolerance to DNA. , 1974, Journal of immunology.

[3]  B. Stollar,et al.  Prevention of Murine Lupus Nephritis by Carrier-Dependent Induction of Immunologic Tolerance to Denatured DNA , 1973, Science.

[4]  G. Bole,et al.  Augmented incidence of neoplasia in NZB-NZW mice treated with long-term cyclophosphamide. , 1973, The Journal of laboratory and clinical medicine.

[5]  H. J. Goldsmith,et al.  Cyclophosphamide therapy and sterility. , 1972, Lancet.

[6]  A. Steinberg,et al.  Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone. , 1972, Arthritis and rheumatism.

[7]  A. Steinberg,et al.  Cytotoxic drugs in treatment of nonmalignant diseases. , 1972, Annals of internal medicine.

[8]  B. Siegel,et al.  Influence of Cytoxan and Poly I·C on Early Antinuclear Antibody Responses in New Zealand Black Mice 1 , 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  V. Beral,et al.  Insensitivity of respiratory centre to carbon dioxide in the Enga people of New Guinea. , 1971, Lancet.

[10]  A. Steinberg,et al.  Cyclophosphamide in lupus nephritis: a controlled trial. , 1971, Annals of internal medicine.

[11]  H. Kunkel,et al.  ANTIBODIES TO POLYNUCLEOTIDES IN HUMAN SERA: ANTIGENIC SPECIFICITY AND RELATION TO DISEASE , 1971, The Journal of experimental medicine.

[12]  J. Miller,et al.  Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. , 1971, The American journal of medicine.

[13]  A. Steinberg,et al.  The role of NZB-NZW F1 thymus in experimental tolerance and auto-immunity. , 1970, Arthritis and rheumatism.

[14]  G. L. Floersheim.  A comparative study of the effects of anti-tumour and immunosuppressive drugs on antibody-forming and erythropoietic cells. , 1970, Clinical and experimental immunology.

[15]  Sharp Gc,et al.  Autoantibodies: friend or foe? , 1970 .

[16]  T. Casey.  Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis. , 1968, Blood.

[17]  A. Aisenberg,et al.  The thymus and recovery from cyclophosphamide-induced tolerance to sheep erythrocytes. , 1968 .

[18]  J. D. Hicks,et al.  Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice. , 1968, Lancet.

[19]  P. Lambert,et al.  PATHOGENESIS OF THE GLOMERULONEPHRITIS OF NZB/W MICE , 1968, The Journal of experimental medicine.

[20]  F. Dietrich.  The immune response to heterologous red cells in mice. , 1966, Immunology.

[21]  J. Marmur.  A procedure for the isolation of deoxyribonucleic acid from micro-organisms , 1961 .

[22]  P. Schur,et al.  Development of reticulum cell sarcoma during cyclophosphamide therapy. , 1974, Arthritis and rheumatism.

[23]  A. Steinberg.  Efficacy of immunosuppressive drugs in rheumatic diseases. , 1973, Arthritis and rheumatism.

[24]  E. Hurd.  Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate. , 1973, Arthritis and rheumatism.

[25]  J. Decker.  Toxicity of immunosuppressive drugs in man. , 1973, Arthritis and rheumatism.

[26]  H. Paulus,et al.  Immunosuppressive therapy: guidelines for drug dosage. Depression of bone marrow granulocyte reserves in systemic lupus erythematosus. , 1972, Arthritis and rheumatism.

[27]  R. Schwartz,et al.  On the mechanism of immunological tolerance in cyclophosphamide-treated mice. , 1970, Clinical and experimental immunology.